Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Glaxosmithkline Pharmaceuticals
Large Cap•3,211 Employees•IPO 1994
Current Price
₹2483.00
-2.9 (-0.12%)Updated
Today's Range
₹2480.00
₹2525.00
₹2483.00
52 Week Range
52W Low₹2220.30
52W High₹3515.70
₹2483.00
Downside11.83%
Upside41.59%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹44,142.98 Cr
Market Cap
Total market value of companyP/E Ratio
43.24
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
26.38
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹60.26
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
28.44%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
63.20%
ROCE
Return on Capital Employed. >15% is goodNet Margin
26.86%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
58.26%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
3.06%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-1.16%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
12.40%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.01
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹115.19
Book Value
Net asset value per shareDividend Yield
3.32%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
75.00%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Glaxo boasts a robust Return on Equity (ROE) of 46.90% and Return on Capital Employed (ROCE) of 63.20%, significantly above industry averages. This highlights efficient capital utilization and superior profitability, showcasing strong operational performance.
- •Glaxo maintains a remarkably low debt-to-equity ratio of 0.01, signifying a very strong financial position with minimal reliance on external borrowing. This robust balance sheet provides significant stability and resilience against economic downturns.
Weaknesses
4 points- •Glaxo's Price-to-Earnings (P/E) ratio of 47.10 is relatively high compared to many industry peers, suggesting potential overvaluation. Investors should carefully assess this metric, considering the possibility of future price corrections and lower returns.
- •The company experienced a slight decline in quarterly sales, with a variance of -1.16%. This negative sales growth could indicate challenges in market demand or increased competition, warranting close monitoring for sustained revenue generation.
Opportunities
3 points- •The broader Pharmaceuticals and Healthcare sector offers significant growth potential due to increasing global healthcare expenditure, an aging population, and continuous innovation in drug discovery. Glaxo is well-positioned to capitalize on these favorable industry trends.
- •Expansion into emerging markets or diversification into new therapeutic areas presents a substantial growth opportunity for Glaxo. Leveraging its strong R&D capabilities could unlock new revenue streams and enhance market penetration.
Threats
4 points- •Intense competition from both domestic and international pharmaceutical players poses a significant threat to market share and pricing power. Aggressive R&D by rivals could erode Glaxo's competitive edge in key therapeutic segments.
- •Strict and evolving regulatory landscapes, including drug pricing controls and quality compliance, present ongoing operational and financial risks. Non-compliance could lead to penalties or market withdrawal of key products.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹2602.00 | +₹119.00 | +4.79% |
| R3 | ₹2557.00 | +₹74.00 | +2.98% |
| R2 | ₹2541.00 | +₹58.00 | +2.34% |
| R1 | ₹2512.00 | +₹29.00 | +1.17% |
| PIVOT | ₹2496.00 | 13.00 | 0.52% |
| CURRENT | ₹2483.00 | - | - |
| S1 | ₹2377.00 | -₹106.00 | -4.27% |
| S2 | ₹2422.00 | -₹61.00 | -2.46% |
| S3 | ₹2451.00 | -₹32.00 | -1.29% |
| S4 | ₹2467.00 | -₹16.00 | -0.64% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-30.4% vs avg
0.52L
(04 Mar 2026)Delivery %+3.0% vs avg
58.7%
(04 Mar 2026)Avg Volume (20D)20-day average
0.75L
(04 Feb - 04 Mar)Avg Delivery %Trend ↑
55.7%
(04 Feb - 04 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Pfizer Ltd
3.28 %
Peer Comparison
| Company Name |
|---|
 Abbott India Ltd |
 Ajanta Pharma Ltd |
 Alkem Laboratories Ltd |
 Aurobindo Pharma Ltd |
 Cohance Lifesciences Ltd |
 Emcure Pharmaceuticals Ltd |
 Gland Pharma Ltd |
 Glenmark Pharmaceuticals Ltd |
 Ipca Laboratories Ltd |
 J B Chemicals & Pharmaceuticals Ltd |
 Laurus Labs Ltd |
 Pfizer Ltd |
 Piramal Pharma Ltd |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
Glaxosmithkline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Limited (GSK) is a major pharmaceutical company with a global presence, including significant operations in India. Its core business revolves around the manufacturing, distribution, and trading of a wide range of pharmaceutical products. The company's history stretches back to 1924, with its current name adopted in 2001. GSK's headquarters are located in Mumbai, India.
A substantial portion of GSK's business focuses on vaccines. Their portfolio includes Infanrix Hexa (for multiple infant diseases), Synflorix (pneumococcal diseases), Havrix (Hepatitis A), Menveo (meningococcal disease), Boostrix (diphtheria, tetanus, and pertussis), Fluarix Tetra (influenza), Varilrix (varicella), and Shingrix (herpes zoster). This extensive vaccine range caters to various age groups and disease preventions, establishing GSK as a key player in the global vaccine market.
Beyond vaccines, GSK offers a diverse portfolio of specialty medicines. Key examples include NUCALA, used to treat severe eosinophilic conditions like asthma, and TRELEGY ELLIPTA, a treatment for chronic obstructive pulmonary disease (COPD). These specialty medications target specific, often chronic, conditions, reflecting GSK's commitment to developing advanced therapies.
GSK also provides a broad selection of general medicines. This includes antibiotics like AUGMENTIN and CEFTUM for bacterial infections, various formulations for mineral and vitamin deficiencies (CobadexCZS, CCM), pain relievers (CALPOL), treatments for hypothyroidism (ELTROXIN), skin creams and ointments (Flutivate, Tenovate, BETNOVATE, PHYSIOGEL, NEOSPORIN, T-BACT) addressing a wide range of dermatological needs. This segment underscores GSK's commitment to providing accessible and widely used treatments for common ailments.
In summary, GlaxoSmithKline Pharmaceuticals Limited operates across multiple sectors of the pharmaceutical industry, offering a comprehensive range of vaccines, specialty medicines targeting complex conditions, and a large selection of general medicines for everyday health concerns. This diversified approach positions GSK as a significant player in the global pharmaceutical market.
COMPANY FACTS - GLAXO
Registered Address
Dr Annie Besant Road, Worli
Mumbai
MAHARASHTRA
IN
Tel: 912224959595
Website:https://india-pharma.gsk.com/en-in/
Investor Relations:http://india-pharma.gsk.com/en-in/investors/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 3,211
IPO Date: 03/11/1994
MANAGEMENT - GLAXO
Ms. Renu Karnad
Non-Executive Chairman of the Board
Mr. Juby Chandy
Chief Financial Officer, Whole Time Director
Mr. Chinmay Sharma
Executive Vice President of Human Resources
Ms. S. Choudhary
Executive Vice President - Regulatory Affairs
Mr. Carson Dalton
Executive Vice President, Communications and Government Affairs
Mr. Ransom D'Souza
Executive Vice President - Communications and Government Affairs
Dr. Shalini Menon
Executive Vice President - Medical Affairs
Mr. Shourov Mukherjee
Executive Vice President - Adult Vaccines
Mr. Amit Pandey
Executive Vice President - Legal
Mr. Upendra Singh
Executive Vice President - General Medicines
Mr. Ritesh Manchanda
Vice President - Customer Supply Chain
Ms. Sharmishta Mitra
Vice President - Paediatric Vaccines
Investor Questions Answered
Glaxosmithkline Pharmaceuticals Ltd (GLAXO) Stock FAQs
Get answers to the most common questions about Glaxosmithkline Pharmaceuticals Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) is ₹2,483. Today, the stock has declined by ₹2.90 (0.12%), trading in a range of ₹2,480 to ₹2,525. The stock opened at ₹2,487 with a trading volume of 11,479 shares.
Glaxosmithkline Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹44,142.98 crores, P/E ratio of 43.24, ROE of 28.44%, and ROCE of 63.20%. The dividend yield stands at 3.32%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) is ₹3,515.7, while the 52-week low is ₹2,220.3. Currently trading at ₹2,483, the stock is 20.3% away from its 52-week low and 29.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Glaxosmithkline Pharmaceuticals Ltd stock at ₹2,483 depends on multiple factors. The stock is currently trading with a P/E ratio of 43.24 and P/B ratio of N/A. Today's performance shows a loss of 0.12%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Glaxosmithkline Pharmaceuticals Ltd offers a dividend yield of 3.32%, which means for every ₹100 invested at the current price of ₹2,483, you can expect to receive approximately ₹3.32 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Glaxosmithkline Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 43.24, P/B Ratio: N/A, ROE: 28.44%, ROCE: 63.20%, Dividend Yield: 3.32%, EPS: ₹60.26, Book Value: ₹115.19, Debt-to-Equity: 0.01, and Current Ratio: N/A. The company's market cap stands at ₹44,142.98 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Glaxosmithkline Pharmaceuticals Ltd stock opened at ₹2,487 and is currently trading at ₹2,483, showing a decline of ₹2.90 (0.12%). The intraday high is ₹2,525 and low is ₹2,480. The trading volume stands at 11,479 shares, indicating moderate market participation today.
Glaxosmithkline Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 43.24, which means investors are willing to pay ₹43.24 for every ₹1 of earnings. With an EPS of ₹60.26, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of ₹44,142.98 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹2,483) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Glaxosmithkline Pharmaceuticals Ltd has a book value of ₹115.19 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹2,483, which is 2055.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Glaxosmithkline Pharmaceuticals Ltd has a Return on Equity (ROE) of 28.44% and Return on Capital Employed (ROCE) of 63.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. Both metrics are strong, indicating efficient capital utilization. Higher percentages generally indicate better financial performance.
Glaxosmithkline Pharmaceuticals Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Glaxosmithkline Pharmaceuticals Ltd has a debt-to-equity ratio of 0.01, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Glaxosmithkline Pharmaceuticals Ltd has an Earnings Per Share (EPS) of ₹60.26, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹2,483 and P/E ratio of 43.24, investors are paying 43.24 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Glaxosmithkline Pharmaceuticals Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Glaxosmithkline Pharmaceuticals Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Glaxosmithkline Pharmaceuticals Ltd stock, consider: 1) Fundamental Analysis - Review P/E (43.24), ROE (28.44%), debt-to-equity (0.01), and growth rates. 2) Technical Analysis - Check 52-week range (₹2220.30 - ₹3515.70), moving averages, and chart patterns. 3) Valuation - Compare current price (₹2483.00) with book value (₹115.19) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Glaxosmithkline Pharmaceuticals Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹2,483 is 24730x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Glaxosmithkline Pharmaceuticals Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹2220.30 - ₹3515.70). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.01 indicates leverage. 4) Liquidity Risk - Based on trading volume of 11,479 shares. 5) Valuation Risk - P/E of 43.24 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Glaxosmithkline Pharmaceuticals Ltd operates in the industry with key metrics: P/E ratio of 43.24, ROE of 28.44%, market cap of ₹44,142.98 crores, and dividend yield of 3.32%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.01), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Glaxosmithkline Pharmaceuticals Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹2,483, with a 52-week range of ₹2220.30 to ₹3515.70. Based on fundamentals like P/E (43.24), ROE (28.44%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Glaxosmithkline Pharmaceuticals Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹2483.00. 2) Fundamental Deterioration - Declining ROE (currently 28.44%), increasing debt (D/E: 0.01), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Glaxosmithkline Pharmaceuticals Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 3.32%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu